Tag: biotechnology

Pharmaceutical giant Takeda is expanding its AI-driven drug discovery efforts by entering into a significant multi-year research collaboration with Nabla Bio. This partnership, potentially worth over $1 billion, will leverage Nabla Bio's proprietary generative AI platform, JAM, for the *de novo* design of antibodies and other protein therapeutics, aiming to accelerate the development of novel treatments for challenging diseases.

Insilico Medicine is challenging the status quo in AI drug discovery by emphasizing measurable benchmarks over industry rhetoric. CEO Alex Zhavoronkov advocates for a competitive approach, focusing on tangible results like faster, cheaper, and higher-quality drug development, rather than speculative claims. The company

Nanyang Biologics Pte. Ltd. has entered into a $1.5 billion business combination agreement with RF Acquisition Corp II, signaling its intent to become a publicly listed company on Nasdaq. This move highlights the growing significance of AI in revolutionizing drug discovery and development, with Nanyang Biologics at the forefront.

Nabla Bio and Takeda have announced a significant expansion of their partnership, entering a multi-year collaboration potentially exceeding $1 billion to develop AI-driven protein therapeutics. This deal leverages Nabla Bio's proprietary Joint Atomic Model (JAM) platform to accelerate Takeda's early-stage drug discovery programs, focusing on novel antibody design and other custom biologics.

A novel Quantum Machine Learning framework, QVT, integrates diverse biochemical data to achieve a breakthrough in accurately predicting enzyme functions, surpassing traditional methods.